BR112016012237A2 - - Google Patents

Info

Publication number
BR112016012237A2
BR112016012237A2 BR112016012237A BR112016012237A BR112016012237A2 BR 112016012237 A2 BR112016012237 A2 BR 112016012237A2 BR 112016012237 A BR112016012237 A BR 112016012237A BR 112016012237 A BR112016012237 A BR 112016012237A BR 112016012237 A2 BR112016012237 A2 BR 112016012237A2
Authority
BR
Brazil
Application number
BR112016012237A
Other languages
Portuguese (pt)
Other versions
BR112016012237B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016012237A2 publication Critical patent/BR112016012237A2/pt
Publication of BR112016012237B1 publication Critical patent/BR112016012237B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112016012237-2A 2013-12-06 2014-12-05 Métodos úteis na síntese de análogos de halicondrina b BR112016012237B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912714P 2013-12-06 2013-12-06
US61/912,714 2013-12-06
PCT/US2014/068834 WO2015085193A1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs

Publications (2)

Publication Number Publication Date
BR112016012237A2 true BR112016012237A2 (enExample) 2017-08-08
BR112016012237B1 BR112016012237B1 (pt) 2023-02-07

Family

ID=53270478

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012237-2A BR112016012237B1 (pt) 2013-12-06 2014-12-05 Métodos úteis na síntese de análogos de halicondrina b

Country Status (13)

Country Link
US (4) US9303039B2 (enExample)
EP (2) EP3505520A1 (enExample)
JP (3) JP6443812B2 (enExample)
CN (1) CN105916861B (enExample)
BR (1) BR112016012237B1 (enExample)
CA (1) CA2931788C (enExample)
ES (1) ES2723355T3 (enExample)
HU (1) HUE043088T2 (enExample)
IL (4) IL245661A0 (enExample)
MX (3) MX376869B (enExample)
RU (1) RU2676486C1 (enExample)
SG (2) SG10201805024YA (enExample)
WO (1) WO2015085193A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
US8598373B2 (en) 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体
CN114716453A (zh) 2013-11-04 2022-07-08 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
JP6443812B2 (ja) * 2013-12-06 2018-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類縁体の合成に有用な方法
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
WO2016179607A1 (en) 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX377663B (es) 2016-02-12 2025-03-11 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
MX390072B (es) 2016-06-30 2025-03-20 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
HUE060466T2 (hu) 2017-04-05 2023-03-28 Harvard College Makrociklusos vegyület és alkalmazása
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2018217894A1 (en) * 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
ES2974243T3 (es) 2017-11-15 2024-06-26 Harvard College Compuestos macrocíclicos y usos de los mismos
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN111868044B (zh) 2018-01-03 2024-07-19 卫材R&D管理有限公司 可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物
CN112437775A (zh) * 2018-07-20 2021-03-02 雷迪博士实验室有限公司 用于制备艾日布林及其中间体的纯化方法
CN113166096A (zh) * 2018-10-09 2021-07-23 雷迪博士实验室有限公司 制备艾立布林的方法及其中间体
US20220089607A1 (en) * 2018-11-28 2022-03-24 Natco Pharma Limited Process for the preparation of high pure eribulin and its mesylate salt
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2022101931A1 (en) * 2020-11-10 2022-05-19 Natco Pharma Limited Process for the preparation of eribulin and its intermediates
CN113354659B (zh) * 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
CN114380840B (zh) * 2022-01-27 2024-01-26 江苏慧聚药业股份有限公司 艾日布林的合成
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (enExample) 1992-09-09 1995-09-01 Hoechst Ag
US6194586B1 (en) * 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
CN1216051C (zh) 1998-06-17 2005-08-24 卫材株式会社 大环类似物及其使用和制备的方法
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
CN109180615A (zh) * 2004-06-03 2019-01-11 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
EP2522663B1 (en) * 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
CA2705383A1 (en) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
US8598373B2 (en) * 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
EP2831082B1 (en) 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
CA2916537C (en) 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN114716453A (zh) 2013-11-04 2022-07-08 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
JP6443812B2 (ja) * 2013-12-06 2018-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類縁体の合成に有用な方法
WO2016179607A1 (en) 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX377663B (es) 2016-02-12 2025-03-11 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
MX390072B (es) 2016-06-30 2025-03-20 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.

Also Published As

Publication number Publication date
MX2020004855A (es) 2021-07-08
MX376869B (es) 2025-03-07
WO2015085193A1 (en) 2015-06-11
US10030032B2 (en) 2018-07-24
US9695188B2 (en) 2017-07-04
US20160176895A1 (en) 2016-06-23
SG10201805024YA (en) 2018-07-30
CN105916861A (zh) 2016-08-31
US20150158881A1 (en) 2015-06-11
IL281275A (en) 2021-04-29
IL245661A0 (en) 2016-06-30
EP3077399A1 (en) 2016-10-12
US20190010166A1 (en) 2019-01-10
EP3077399B1 (en) 2019-02-20
MX370611B (es) 2019-12-18
IL273736B (en) 2021-03-25
RU2676486C1 (ru) 2018-12-29
MX2016006891A (es) 2017-06-12
JP2016540752A (ja) 2016-12-28
IL265640A (en) 2019-05-30
JP2019031530A (ja) 2019-02-28
US10450324B2 (en) 2019-10-22
MX2019011926A (es) 2019-11-18
JP2020059739A (ja) 2020-04-16
JP6634135B2 (ja) 2020-01-22
IL273736A (en) 2020-05-31
US20170298078A1 (en) 2017-10-19
IL265640B (en) 2020-04-30
BR112016012237B1 (pt) 2023-02-07
MX384292B (es) 2025-03-14
US9303039B2 (en) 2016-04-05
CA2931788A1 (en) 2015-06-11
EP3077399A4 (en) 2017-05-10
ES2723355T3 (es) 2019-08-26
EP3505520A1 (en) 2019-07-03
SG11201604545XA (en) 2016-07-28
CA2931788C (en) 2022-05-24
JP6905041B2 (ja) 2021-07-21
IL281275B (en) 2021-12-01
HUE043088T2 (hu) 2019-08-28
JP6443812B2 (ja) 2018-12-26
CN105916861B (zh) 2018-12-14

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112015007533A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014018480A2 (enExample)
BR112014020341A2 (enExample)
BR112014017855A2 (enExample)
BR112016012237A2 (enExample)
BR112014017765A2 (enExample)
BR112014017669A2 (enExample)
BR112016014583A2 (enExample)
BR112016012525A2 (enExample)
BR112016008415A2 (enExample)
BR112014018468A2 (enExample)
BR112014017901A2 (enExample)
BR112014018207A2 (enExample)
BR112015015948A2 (enExample)
BR112016008673A2 (enExample)
BR112014017722A2 (enExample)
BR112016008389A2 (enExample)
BR112014017653A2 (enExample)
BR112014017794A2 (enExample)
BR112016013745A2 (enExample)
BR112014017601A2 (enExample)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 491/22

Ipc: C07D 491/22 (2006.01), A61P 35/00 (2006.01)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2014, OBSERVADAS AS CONDICOES LEGAIS